Optical coherence tomography for diagnosing recurrent or residual basal cell carcinoma after topical treatment: A diagnostic cohort study - 16/09/23
, Fieke Adan, MD, PhD a, b, Patricia Joan Nelemans, MD, PhD c, Aniek Defauwes, MD d, Klara Mosterd, MD, PhD a, bAbstract |
Background |
Recurrent/residual basal cell carcinoma (BCC) after topical treatment may not be visible during clinical and dermatoscopic examination (CDE). Optical coherence tomography (OCT) may detect these subclinical recurrences or residues.
Objective |
To compare the diagnostic accuracy of CDE with that of CDE combined with OCT (CDE-OCT) for detecting recurrent/residual BCC after topical treatment of superficial BCC.
Methods |
In this diagnostic cohort study, the suspicion level for recurrence or residue was recorded on a 5-point confidence scale. All patients with high suspicion of recurrence or residue based on CDE and/or CDE-OCT were referred for punch biopsy. Patients with a low suspicion on CDE and CDE-OCT were asked to (voluntarily) undergo a control biopsy. Histopathologic results of the biopsy were used for verification of CDE and CDE-OCT diagnoses (gold standard).
Results |
This study included 100 patients. A histopathologic recurrent/residual BCC was found in 20 patients. For recurrence or residue detection, sensitivity was 100% (20 of 20) for CDE-OCT and 60% (12 of 20) for CDE (P = .005) and specificity was 95% for CDE-OCT and 96.3% for CDE (P = .317). The area under the curve for CDE-OCT (0.98) was significantly higher than that for CDE (0.77) (P = .001).
Limitations |
Results are based on 2 OCT assessors.
Conclusion |
Compared with CDE alone, CDE-OCT results in a significantly higher ability to detect recurrent/residual BCCs after topical treatment.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, follow-up, imaging, optical coherence tomography, recurrence, residue, topical treatment
Abbreviations used : AUC, BCC, CDE, NPV, OCT, sBCC
Plan
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved (Medisch-ethische toetsingscommissie azM/UM: NL74245.068.20/METC20-046). |
Vol 89 - N° 4
P. 728-733 - octobre 2023 Retour au numéro
Article précédent
- Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies
- James Del Rosso, Jeffrey Sugarman, Lawrence Green, Theodore Lain, Ofra Levy-Hacham, Rinat Mizrahi, Linda Stein Gold
- Understanding melanoma in situ: Lentigo maligna surgical treatment terminology and guideline adherence, a targeted review
- Tatiana Abrantes, Allison Robbins, Benjamin Kahn, Sara Yumeen, R. Scott Bukoski, Oliver Wisco, Leslie Robinson-Bostom, John Kawaoka, Tiffany Libby, Hayley Goldbach, Dillon Imbriano, Leonardo Lizbinski, Megan Tran, Samer Wahood, Aakash Mehta, Thomas Miner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?